Dengvaxia® [Dengue Vaccine]

The Brazilian regulatory authorities ANVISA approved Dengvaxia®, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas. Dengvaxia® was shown to reduce dengue due to all four serotypes in two-thirds of the participants and prevent 8 out of 10 hospitalizations due to dengue and up to 93% of severe dengue cases.

http://centerforvaccineethicsandpolicy.net/2016/01/03/dengvaxia-dengue-vaccine-receives-regulatory-approval-in-brazil-philippines/